The effect of XXXX in an improved intracranial 9L gliosarcoma @entity35 model.

@entity1 @entity353 @entity1313 @entity5 @entity10822 @entity19525 @entity35 @entity204
Angiogenesis is a process fundamental to the growth of many solid @entity5 . Agents that inhibit angiogenesis may have a role in preventing @entity5 growth. @entity10822 , a synthetic analogue of @entity19525 , has been shown to inhibit @entity5 growth in several extracranial @entity5 models. Its use has been reported to have minimal side effects. No studies have been reported using @entity10822 in the treatment of an @entity5 . To determine the effect of @entity10822 on an @entity5 , we used an improved implantation technique to place 80,000 9L @entity5 cells into the right caudate nucleus of 25 male Fischer 344 @entity35 . Starting on the first post-implantation day, 12 animals received 30 mg kg-1 @entity10822 via intraperitoneal injection every other day until @entity204 . Thirteen control animals received vehicle only. Evidence of @entity5 was apparent in 22/23 animals (96%). All animals treated with @entity10822 experienced a progressive and significant @entity353 when compared to controls. At day 17, treated animals retained 80.0 +/- 2.2% of their initial weight, (mean +/- SD) compared to 100.9 +/- 3.6% for controls (p = 2.25 x 10(-12); student's t-test). @entity10822 had no effect on survival. Median survival in the treatment group was 24.5 days compared to 25 days in the controls (p = 0.95; Mann-Whitney). @entity10822 , although promising in @entity5 models, may not be as effective in controlling the growth of @entity5 , and its use is not without significant systemic effects. More studies are needed before this drug is used in @entity1 @entity1313 trials.(ABSTRACT TRUNCATED AT 250 WORDS)
